Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine

United States Army Medical Research and Development Command (USAMRDC)

Status and phase

Completed

Phase 1

Conditions

Dengue

Treatments

Biological: D1ME100 (dengue-1 premembrane/envelope DNA vaccine)

Study type

Interventional

Funder types

Other U.S. Federal agency

Identifiers

NCT00290147

62787A 810S A0235 (Other Identifier)

WRAIR 1191 (Other Identifier)

NMRC 2004.0002

HSRRB A-13304 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to exame the safety of a DNA vaccine against dengue-1.

Full description

Dengue is a desease that affects 100 million people throughout the world mainly in tropical countries in the South Pacific, Asia, the Caribbean, and Africa. The disease often presents with high fever, severe headache, and joint/muscle pain that usually goes away on its own, but it can also present as a sometimes deadly hemorrhagic (bleeding) disease. Humans catch this disease by being bitten by mosquitoes that have been infected with dengue virus. Scientists at the Naval Medical Research Center have been working on vaccines to prevent dengue disease. This vaccine, referred to as D1ME, is an experimental DNA vaccine that contains genes from the dengue-1 virus. The purpose of this study is to test the safety of a new experimental vaccine against dengue and to see if the vaccine can stimulate the immune system.

Enrollment

22 patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Available to participate for the duration of the study (approximately 12 months)
Completion and review of knowledge assement quiz

Exclusion criteria

Pregnant (by history or as ascertained by pregnancy test) or lactating female
Female who intends to become pregnant during the study
Plan to have elective surgery during the study period
HIV infection
Known immunodeficiency or currently receiving immunosuppressive therapy (inhaled and topical steroids are allowed)
History of splenectomy
Administration of a vaccine not foreseen by the study protocol during the period starting 30 days before each dose of vaccine and ending 30 days after vaccination
Evidence of active (acute or chronic) hepatitis B or C infection
Autoimmune diseaseor subjects who describe a first-degree relative with clearly documented autoimmune disease
Acute or chronic, clinically significant cardiac, pulmonary, hepatic, or renal abnormality, as determined by physical examination or basic laboratory screening
Clinical or laboratory evidence of significant anemia
History of flavivirus infection or previous receipt of flavivirus vaccine
Positive serology for flaviviruses (all four dengue virus serotypes, Japanese encephalitis, Yellow fever virus, and West Nile virus), HIV-1, Hepatitis B surface antigen, or anti-hepatitis C virus antibodies prior to enrollment
Use of any investigational or non-registered drug or vaccine other than the study vaccine within 60 days preceding the first dose of study vaccine, or planned use during the study period.
Previous history of allergic or anaphylactic reaction to any vaccine
Planned travel to areas with endemic dengue during the study period
Any other significant finding which, in the opinion of the investigator, would increase the risk of having an adverse outcome from participating in this protocol